title: [Issues around testicular carcinoma].
abstract: Testicular carcinoma is a rare tumour but the most frequently occurring form of cancer in men aged 18-35 years. In metastatic disease, following orchidectomy three or four courses of combination chemotherapy with cisplatin are given. With a general chance of cure of 80-90%, testicular cancer is still regarded as a model for a form of cancer that is curable. Due to this favourable prognosis--and to its rising incidence--the group of people who survive testicular cancer is growing and more attention is being paid to the risk of adverse consequences of treatment: secondary tumours and cardiovascular morbidity. Shared care follow-up for testicular cancer survivors with participation of both primary and secondary care is currently developed.
authors.affiliation: Universitair Medisch Centrum Groningen, afd. Medische Oncologie, Groningen, the Netherlands.
authors.forename: Janine
authors.initials: J
authors.lastname: Nuver
authors.forename: Sjoukje F
authors.initials: SF
authors.lastname: Oosting
authors.forename: Jourik A
authors.initials: JA
authors.lastname: Gietema
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D002277:Carcinoma / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D009919:Orchiectomy; D011379:Prognosis; D013736:Testicular Neoplasms / Q000628:therapy*; D055815:Young Adult